NASDAQ:MIRA MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis $0.80 -0.03 (-4.12%) As of 01:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MIRA Pharmaceuticals Stock (NASDAQ:MIRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MIRA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.73▼$0.8450-Day Range$0.83▼$1.2852-Week Range$0.51▼$5.01Volume226,901 shsAverage Volume1.92 million shsMarket Capitalization$13.45 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingBuy Company OverviewMIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.Read More… Remove Ads MIRA Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreMIRA MarketRank™: MIRA Pharmaceuticals scored higher than 35% of companies evaluated by MarketBeat, and ranked 681st out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingMIRA Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMIRA Pharmaceuticals has received no research coverage in the past 90 days.Read more about MIRA Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MIRA Pharmaceuticals are expected to grow in the coming year, from ($0.60) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MIRA Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MIRA Pharmaceuticals is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMIRA Pharmaceuticals has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about MIRA Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.97% of the float of MIRA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMIRA Pharmaceuticals has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MIRA Pharmaceuticals has recently increased by 38.88%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMIRA Pharmaceuticals does not currently pay a dividend.Dividend GrowthMIRA Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.97% of the float of MIRA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMIRA Pharmaceuticals has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MIRA Pharmaceuticals has recently increased by 38.88%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.44 News SentimentMIRA Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for MIRA Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for MIRA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows5 people have added MIRA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MIRA Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.65% of the stock of MIRA Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 35.16% of the stock of MIRA Pharmaceuticals is held by institutions.Read more about MIRA Pharmaceuticals' insider trading history. Receive MIRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MIRA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address MIRA Stock News HeadlinesMIRA Pharmaceuticals (MIRA) Expected to Announce Quarterly Earnings on MondayApril 5 at 1:29 AM | americanbankingnews.comWhat is Zacks Small Cap's Estimate for MIRA FY2026 Earnings?April 4 at 2:41 AM | americanbankingnews.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 7, 2025 | Porter & Company (Ad)Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2April 2, 2025 | markets.businessinsider.comMIRA Enrolls Patients Amid Rapid ProgressApril 2, 2025 | msn.comMIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 38.9% in MarchMarch 31, 2025 | americanbankingnews.comMira Pharmaceuticals signs binding LOI to acquire SKNY PharmaceuticalsMarch 25, 2025 | markets.businessinsider.comMIRA Pharmaceuticals in binding LOI to acquire SKNY PharmaceuticalsMarch 25, 2025 | markets.businessinsider.comSee More Headlines MIRA Stock Analysis - Frequently Asked Questions How have MIRA shares performed this year? MIRA Pharmaceuticals' stock was trading at $1.14 on January 1st, 2025. Since then, MIRA shares have decreased by 29.8% and is now trading at $0.80. View the best growth stocks for 2025 here. How were MIRA Pharmaceuticals' earnings last quarter? MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) posted its quarterly earnings results on Friday, March, 28th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.14. When did MIRA Pharmaceuticals IPO? MIRA Pharmaceuticals (MIRA) raised $9 million in an IPO on Thursday, August 3rd 2023. The company issued 1,275,000 shares at $7.00 per share. How do I buy shares of MIRA Pharmaceuticals? Shares of MIRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MIRA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that MIRA Pharmaceuticals investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Ovid Therapeutics (OVID), Alamos Gold (AGI) and GeoVax Labs (GOVX). Company Calendar Last Earnings3/28/2025Today4/07/2025Next Earnings (Estimated)4/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MIRA Previous SymbolNASDAQ:MIRA CIK1904286 Webmirapharmaceuticals.com Phone737-289-0835FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$14.00 High Stock Price Target$17.00 Low Stock Price Target$11.00 Potential Upside/Downside+1,645.6%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-337.44% Return on Assets-280.58% Debt Debt-to-Equity RatioN/A Current Ratio6.11 Quick Ratio6.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book2.67Miscellaneous Outstanding Shares16,814,000Free Float15,460,000Market Cap$13.48 million OptionableNot Optionable Beta2.05 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:MIRA) was last updated on 4/7/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThinking of buying Nvidia? Read this firstI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.